EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the recommended first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR-TKI sensitizing mutations (EGFRm)1.